Objective Single nucleotide variants have been implicated in the response to fertility
treatment and a pharmacogenomic approach may help to customize therapy based on …

Purpose To evaluate the association of single-nucleotide polymorphisms (SNPs) in the anti-
Müllerian hormone (AMH) and AMH type II receptor (AMHR2) genes with ovarian response …

BACKGROUND Polycystic ovaries display an increased number of pre-antral and antral
follicles compared with normal ovaries, suggesting that early and late follicle development …

Objective The aim of this study is to assess the role of AMH in prediction of poor ovarian
response as well as the relation between ESR 2 (+ 1730G> A)(rs4986938) and FSHR p. Thr …

Background: In human assisted reproduction, the ovarian response to exogenous
recombinant Follicle-stimulating Hormone (FSH) therapy is variable and difficult to predict …

Introduction Obtaining an adequate number of high-quality oocytes is a major challenge in
controlled ovarian hyperstimulation (COH). To date, a range of hormonal and clinical …

Purpose Unpredictability in acquiring an adequate number of high-quality oocytes following
ovarian stimulation is one of the major complications in controlled ovarian hyperstimulation …

Objective To define the landscape of clinically valid genetic associations with IVF treatment
response and outcomes. Design The Clinical Genome (ClinGen) Resource has defined a …

STUDY QUESTION Do polymorphisms in the anti-Müllerian hormone (AMH) promoter have
an effect on AMH levels in patients with polycystic ovary syndrome (PCOS)? SUMMARY …

Objective Our study aimed to investigate the relationship between polymorphisms (Apa1,
Bsm1, Fok1, and Cdx2) in the VDR gene as well as AMH and AMHR2 genes and their …